EP2509630A4 - Delivery system for cytotoxic drugs by bispecific antibody pretargeting - Google Patents
Delivery system for cytotoxic drugs by bispecific antibody pretargetingInfo
- Publication number
- EP2509630A4 EP2509630A4 EP10836680.8A EP10836680A EP2509630A4 EP 2509630 A4 EP2509630 A4 EP 2509630A4 EP 10836680 A EP10836680 A EP 10836680A EP 2509630 A4 EP2509630 A4 EP 2509630A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- delivery system
- bispecific antibody
- cytotoxic drugs
- antibody pretargeting
- pretargeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26799809P | 2009-12-09 | 2009-12-09 | |
US12/644,146 US7981398B2 (en) | 2005-04-06 | 2009-12-22 | PEGylation by the dock and lock (DNL) technique |
US12/731,781 US8003111B2 (en) | 2005-04-06 | 2010-03-25 | Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivo |
US12/752,649 US8034352B2 (en) | 2005-04-06 | 2010-04-01 | Tetrameric cytokines with improved biological activity |
US12/754,740 US8562988B2 (en) | 2005-10-19 | 2010-04-06 | Strategies for improved cancer vaccines |
US12/869,823 US20110020273A1 (en) | 2005-04-06 | 2010-08-27 | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
US12/871,345 US8551480B2 (en) | 2004-02-13 | 2010-08-30 | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
US12/915,515 US20110064754A1 (en) | 2005-03-03 | 2010-10-29 | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
US12/949,536 US8211440B2 (en) | 2005-10-19 | 2010-11-18 | Multivalent immunoglobulin-based bioactive assemblies |
PCT/US2010/059686 WO2011072124A1 (en) | 2009-12-09 | 2010-12-09 | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2509630A1 EP2509630A1 (en) | 2012-10-17 |
EP2509630A4 true EP2509630A4 (en) | 2013-07-17 |
Family
ID=44145913
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10836680.8A Withdrawn EP2509630A4 (en) | 2009-12-09 | 2010-12-09 | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2509630A4 (en) |
CN (1) | CN102665757A (en) |
CA (1) | CA2782398C (en) |
WO (1) | WO2011072124A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103087171B (en) * | 2012-12-24 | 2015-01-14 | 中国人民解放军第四军医大学 | Bispecific antibody of resisting PSMA/FITC (prostate specific membrane antigen/fluorescein isothiocyanate) for early diagnosis and treatment of prostatic cancer and preparation method of bispecific antibody |
JP2018502859A (en) * | 2015-01-09 | 2018-02-01 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | Treatment of tumors with prior targeting using bispecific antibodies |
CN104771764B (en) * | 2015-04-14 | 2018-09-18 | 中国药科大学 | A kind of macrophage target carrier system and its preparation |
CN105367660B (en) * | 2015-12-22 | 2018-12-21 | 深圳市北科生物科技有限公司 | A kind of bispecific antibody of anti-CD16A antigen and anti-MUC1 antigen |
CN109476699B (en) | 2016-06-02 | 2021-10-12 | 艾伯维公司 | Glucocorticoid receptor agonists and immunoconjugates thereof |
US11458208B2 (en) | 2016-06-06 | 2022-10-04 | Asclepiumm Taiwan Co., Ltd | Desmoglein 2 antibody fusion proteins for drug delivery |
HUE054428T2 (en) | 2017-12-01 | 2021-09-28 | Abbvie Inc | Glucocorticoid receptor agonist and immunoconjugates thereof |
AU2019281019A1 (en) * | 2018-06-07 | 2020-11-26 | Oncoone Research & Development Gmbh | Anti-oxMIF/anti-CD3 antibody for cancer treatment |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020040130A1 (en) * | 2000-07-10 | 2002-04-04 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
US20030198595A1 (en) * | 1998-06-22 | 2003-10-23 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US20030232420A1 (en) * | 2002-05-03 | 2003-12-18 | Andreas Braun | Kinase anchor protein muteins, peptides thereof and related documents |
WO2004094613A2 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
US20060154330A1 (en) * | 2002-09-06 | 2006-07-13 | Enno Klussmann | Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
WO2006107786A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
WO2007046893A2 (en) * | 2005-10-19 | 2007-04-26 | Ibc Pharmaceuticals, Inc. | Methods for generating bioactive assemblies and uses thereof |
WO2007075270A2 (en) * | 2005-12-16 | 2007-07-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
WO2007134037A2 (en) * | 2006-05-15 | 2007-11-22 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
WO2009055653A1 (en) * | 2007-10-26 | 2009-04-30 | Ibc Pharmaceuticals, Inc. | Pegylation by the dock and lock (dnl) technique |
US20090191225A1 (en) * | 2005-04-06 | 2009-07-30 | Ibc Pharmaceuticals, Inc. | Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities |
US20090202487A1 (en) * | 2005-04-06 | 2009-08-13 | Ibc Pharmaceuticals, Inc. | Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology |
WO2009126558A1 (en) * | 2008-04-10 | 2009-10-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7052872B1 (en) * | 1999-06-22 | 2006-05-30 | Immunomedics, Inc. | Bi-specific antibodies for pre-targeting diagnosis and therapy |
US7527787B2 (en) | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
CN1882701B (en) * | 2003-09-18 | 2015-11-25 | Posco公司 | Size-controlled macromole |
BRPI0509732A (en) * | 2004-04-09 | 2007-09-25 | Chugai Pharmaceutical Co Ltd | water soluble prodrug, pharmaceutical composition, therapeutic agent, antifungal agent and use of said prodrug |
-
2010
- 2010-12-09 CA CA2782398A patent/CA2782398C/en not_active Expired - Fee Related
- 2010-12-09 EP EP10836680.8A patent/EP2509630A4/en not_active Withdrawn
- 2010-12-09 WO PCT/US2010/059686 patent/WO2011072124A1/en active Application Filing
- 2010-12-09 CN CN2010800526498A patent/CN102665757A/en active Pending
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030198595A1 (en) * | 1998-06-22 | 2003-10-23 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
US20020040130A1 (en) * | 2000-07-10 | 2002-04-04 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
US20030232420A1 (en) * | 2002-05-03 | 2003-12-18 | Andreas Braun | Kinase anchor protein muteins, peptides thereof and related documents |
US20060154330A1 (en) * | 2002-09-06 | 2006-07-13 | Enno Klussmann | Akap18 delta, a novel splicing variant of a protein kinase a anchor protein and the use of the same |
WO2004094613A2 (en) * | 2003-04-22 | 2004-11-04 | Ibc Pharmaceuticals | Polyvalent protein complex |
US20090191225A1 (en) * | 2005-04-06 | 2009-07-30 | Ibc Pharmaceuticals, Inc. | Stably Tethered Structures of Defined Compositions with Multiple Functions or Binding Specificities |
WO2006107786A2 (en) * | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
US20090202487A1 (en) * | 2005-04-06 | 2009-08-13 | Ibc Pharmaceuticals, Inc. | Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology |
WO2007046893A2 (en) * | 2005-10-19 | 2007-04-26 | Ibc Pharmaceuticals, Inc. | Methods for generating bioactive assemblies and uses thereof |
WO2007075270A2 (en) * | 2005-12-16 | 2007-07-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
WO2007134037A2 (en) * | 2006-05-15 | 2007-11-22 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
WO2009055653A1 (en) * | 2007-10-26 | 2009-04-30 | Ibc Pharmaceuticals, Inc. | Pegylation by the dock and lock (dnl) technique |
WO2009126558A1 (en) * | 2008-04-10 | 2009-10-15 | Ibc Pharmaceuticals, Inc. | Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology |
Non-Patent Citations (2)
Title |
---|
D. M. GOLDENBERG ET AL: "Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting", THE JOURNAL OF NUCLEAR MEDICINE, vol. 49, no. 1, 1 January 2008 (2008-01-01), pages 158 - 163, XP055028152, ISSN: 0161-5505, DOI: 10.2967/jnumed.107.046185 * |
See also references of WO2011072124A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011072124A1 (en) | 2011-06-16 |
EP2509630A1 (en) | 2012-10-17 |
CA2782398A1 (en) | 2011-06-16 |
CA2782398C (en) | 2017-09-26 |
CN102665757A (en) | 2012-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL249066A0 (en) | Highly concentrated pharmaceutical formulations comprising anti cd20 antibody | |
HK1258442A1 (en) | Pharmaceutical dosages delivery system | |
IL219301A0 (en) | Dosage regiman for administering a cd19xcd3 bispecific antibody | |
EP2509630A4 (en) | Delivery system for cytotoxic drugs by bispecific antibody pretargeting | |
IL214099A0 (en) | Conjugate based systems for controlled drug delivery | |
IL216306A0 (en) | Pharmaceutical system for trans-membrane delivery | |
PL2654864T3 (en) | System for drug delivery | |
GB2484220B (en) | Dispensing system for medicament regime | |
EP2401012A4 (en) | Drug delivery system | |
PT2398500T (en) | Glutathione-based drug delivery system | |
EP2782630A4 (en) | Drug delivery system with a delay mechanism | |
HK1139053A1 (en) | Nanoparticle delivery systems for membrane-integrating peptides | |
IL212767A (en) | Device for drug delivery | |
EP2540311A4 (en) | Composite body for antigen or drug delivery | |
PL2297500T3 (en) | Actuator for a dosing system | |
IL208386A0 (en) | Lipid-oil-water nanoemulsion delivery system for microtubule-interacting agents | |
IL218637A0 (en) | Dosage regimen for administering an epcamxcd3 bispecific antibody | |
SI2330131T1 (en) | Antibodies against HER2 truncated variant CTF-611 | |
GB0909319D0 (en) | Transluminal delivery system | |
PL2437736T3 (en) | Drug delivery systems | |
IL210393A0 (en) | Administration regime for nitrocatechols | |
IL217072A (en) | Micro carrier for drug delivery | |
PL2568802T3 (en) | Vehicle for displacing feed | |
GB0909435D0 (en) | Nanoparticle for biomolecule delivery | |
EP2699236A4 (en) | Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20120629 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20130613 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/56 20060101ALI20130607BHEP Ipc: C07K 16/24 20060101ALI20130607BHEP Ipc: C07K 14/52 20060101ALI20130607BHEP Ipc: A61K 39/395 20060101ALI20130607BHEP Ipc: C07K 16/46 20060101AFI20130607BHEP Ipc: C07K 16/30 20060101ALI20130607BHEP Ipc: C07K 16/28 20060101ALI20130607BHEP Ipc: A61P 35/00 20060101ALI20130607BHEP Ipc: C07K 16/44 20060101ALI20130607BHEP Ipc: A61K 47/48 20060101ALI20130607BHEP |
|
17Q | First examination report despatched |
Effective date: 20150608 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/00 20060101AFI20180209BHEP |
|
INTG | Intention to grant announced |
Effective date: 20180316 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20181010 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20190221 |